Skip to main content
IMS Events Main banner
Back

    Nizar J. Bahlis, MD

    Associate Professor of Medicine - Hematology and Bone Marrow Transplantation
    Arnie Charbonneau Cancer Institute - University of Calgary
    Calgary, Alberta, Canada

    Dr Bahlis is an Associate Professor of Medicine at the University of Calgary in the division of Hematology and Bone Marrow Transplantation and a member of the Charbonneau Cancer Research Institute. Dr Bahlis received his medical degree in 1995 from St Joseph University - French Faculty of Medicine in Beirut. He then completed his internal Medicine residency at the State University of New York in Syracuse followed by a Hematology-Oncology fellowship at the University of Miami, Florida. Dr Bahlis also completed a postdoctoral fellowship in cancer biology at the University of Miami under the mentorship of Dr Lawrence Boise. Dr Bahlis’ clinical and laboratory research focus on the study of plasma cell dyscrasia, with particular interest in multiple myeloma genomics, single cell immune profiling, mechanisms of drug resistance and the development of novel therapeutics. He has received several awards and research funding from numerous agencies including the ASCO young investigator award, the Multiple Myeloma Research Foundation, The Leukemia and Lymphoma Society of Canada, Alberta Cancer Foundation, the National Institute of Health, the Terry Fox Foundations and the Canadian Institute of Health and Research (CIHR). His research work was published in many peer-reviewed journals including New England Journal of Medicine, Nature Medicine, Cancer Cell, Blood, Journal of Clininal Oncology, Blood Cancer Discovery, Leukemia, Molecular Cancer Research and Clinical Cancer Research. Dr Bahlis also served on the editorial board for the journal Blood and is an associate editor of the jounral Blood. He also serves on the review panel boards of several national and international funding agencies. He is a member of the American Society of Hematology (ASH), American Society of Clinical Oncology and served on the ASH plasma cell dyscrasia scientific panel and is a current member of the international myeloma society (IMS) education panel.

    Disclosure information not submitted.

    Presentation(s):